2018 Round-upMultiple sclerosis in 2018: new therapies and biomarkers
References (8)
- et al.
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Lancet
(2018) - et al.
Phase 2 trial of ibudilast in progressive multiple sclerosis
N Engl J Med
(2018) - et al.
Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis
N Engl J Med
(2018) - et al.
Progression of regional grey matter atrophy in multiple sclerosis
Brain
(2018)
There are more references available in the full text version of this article.
Cited by (10)
Impact of gut microbiota on neurogenesis and neurological diseases during infancy
2020, Current Opinion in PharmacologyCitation Excerpt :In the past seven years, many new cases of multiple sclerosis (MS) have been diagnosed in children. MS is an inflammatory disease characterized by the immune-mediated demyelination of axon [47]. A novel study assessed in MS first-degree family members the intestinal microbiome profiles.
Prognostic Markers in Multiple Sclerosis
2022, Neuroscience and Behavioral PhysiologyMultiple sclerosis in pregnancy and its role in female fertility: A systematic review
2021, Jornal Brasileiro de Reproducao Assistida
© 2018 Elsevier Ltd. All rights reserved.